One Drug, Nearly a Billion Dollars, and a Pipeline That Just Blinked
The short version Krystal Biotech built a profitable, cash-rich business on a single gene therapy approved...
Ardelyx: The Revenue Is Real, the Guidance Cut Is Realer
Three years ago, Ardelyx was burning through cash with almost nothing to show at the pharmacy...
Innoviva: The Royalties Are Shrinking. The Specialty Business Is Growing. Both Things Are True at Once.
Innoviva spent most of its life as a toll booth on two GSK inhalers. Every time...
One Drug Is Carrying the Weight. Two Acquisitions Just Added More.
Three years ago, Tarsus Pharmaceuticals was shrinking. Revenue had fallen by more than half in 2022,...
Nature’s Sunshine: The Margin Is Climbing. The Stock Is Not.
Nature's Sunshine spent most of its life as a quiet Utah supplement maker, selling herbal capsules...
Travere Therapeutics: One Drug, Two Labels, and a Company That Looks Almost Nothing Like It Did Two Years Ago
For most of its life, Travere was a small rare-disease company running hard to stay ahead...
Three FDA Clocks, One Burning Balance Sheet: What BridgeBio’s Latest Filing Actually Shows
Three years ago, BridgeBio Pharma was a research-stage company watching its revenue collapse in a single...
Zoetis: The Margin Holds, the Stock Does Not
Before anything else The 10-K for fiscal year 2025 shows Zoetis earning its widest net margin...
Organogenesis: A Government Pricing Decision Cut Revenue in Half. The Stock Already Knows.
In one breath Organogenesis built a $564 million business selling advanced wound-care products to Medicare patients,...
AbbVie’s October Surprise: A $216 Million Charge and a Pipeline That Keeps Growing Anyway
Two numbers filed within days of each other tell opposite stories about the same company. On...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.